Martin Schäfer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martin Schäfer has a total of 337 co-authors. Here are the top co-authors by number of shared publications:
- Anja Strangfeld
Programmbereich Epidemiologie und Versorgungsforschung, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Deutschland
13 shared publications - Pedro M. Machado
Department of Neuromuscular Diseases, University College London, London, UK
9 shared publications - Saskia Lawson-Tovey
Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK
9 shared publications Anja Strangfeld
German Rheumatism Research Center and Charité University Hospital Berlin Germany
8 shared publications- Jonathan S. Hausmann
Rheumatology, Boston Children's Hospital, Boston, Massachusetts, USA
8 shared publications - Laure Gossec
INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, Team Pepites, Paris, France
7 shared publications
Latest Publications
- Open Access
Beyond Tchakaloff Quadrature: Positive Functionals, Frames and Widths
Tchakaloff's theorem from 1957 asserts the existence of exact quadrature rules with non-negative weights for any polynomial space of finite degree on $\mathbb{R}^d$ if the underlying measure is positive, compactly supported, and absolutely continuous with respect to the Lebesgue measure. This classical result coined the term Tchakaloff quadrature for quadrature that is exact and only uses non-negative weights. It has been a long-standing endeavor, under which conditions such rules exist. A final answer was given in 2012 by Bisgaard with the insight that, in fact, every finite-dimensional space of integrable functions on a positive measure space admits them. In this article we recall this result and provide a major extension to the question of positive discretizability of $\mathbb{C}$-linear functionals on finite-dimensional spaces. We introduce the notion of strict $S$-positivity for such functionals, where $S$ are subsets of the functional's domain, and show the equivalence of positive discretizability to being strictly $S$-positive for a suitable choice of $S$. We further investigate consequences for other discretization problems. One fundamental implication is the guaranteed existence of $L_p$-Marcinkiewicz-Zygmund equalities in finite-dimensional spaces of $p$-integrable functions in case that $p$ is an even integer, another the exact discretizability of any frame in $\mathbb{K}^n$, where $\mathbb{K}\in\{\mathbb{R},\mathbb{C}\}$, if a rescaling of the frame elements is allowed. In addition, we provide bounds for Tchakaloff quadrature widths $κ_n^+$ and, addressing the question of constructibility of discretization points, establish a connection to $D$-optimal design.Open AccessBeyond Tchakaloff Quadrature: Positive Functionals, Frames and Widths
Tchakaloff's theorem from 1957 asserts the existence of exact quadrature rules with non-negative weights for any polynomial space of finite degree on $\mathbb{R}^d$ if the underlying measure is positive, compactly supported, and absolutely continuous with respect to the Lebesgue measure. This classical result coined the term Tchakaloff quadrature for quadrature that is exact and only uses non-negative weights. It has been a long-standing endeavor, under which conditions such rules exist. A final answer was given in 2012 by Bisgaard with the insight that, in fact, every finite-dimensional space of integrable functions on a positive measure space admits them. In this article we recall this result and provide a major extension to the question of positive discretizability of $\mathbb{C}$-linear functionals on finite-dimensional spaces. We introduce the notion of strict $S$-positivity for such functionals, where $S$ are subsets of the functional's domain, and show the equivalence of positive discretizability to being strictly $S$-positive for a suitable choice of $S$. We further investigate consequences for other discretization problems. One fundamental implication is the guaranteed existence of $L_p$-Marcinkiewicz-Zygmund equalities in finite-dimensional spaces of $p$-integrable functions in case that $p$ is an even integer, another the exact discretizability of any frame in $\mathbb{K}^n$, where $\mathbb{K}\in\{\mathbb{R},\mathbb{C}\}$, if a rescaling of the frame elements is allowed. In addition, we provide bounds for Tchakaloff quadrature widths $κ_n^+$ and, addressing the question of constructibility of discretization points, establish a connection to $D$-optimal design. - Open Access
- 20 October 2025
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 85 (1) , 65-69
Neue Erkenntnisse aus dem RABBIT-Register zum Krebsrisiko von Patient:innen mit rheumatoider Arthritis bei Therapie mit Januskinaseinhibitoren
Zusammenfassung: Januskinaseinhibitoren (JAKis) sind sehr wirksame Medikamente zur Behandlung entzündlich rheumatischer Erkrankungen. In der randomisierten Studie ORAL Surveillance wurde gezeigt, dass es bei Patient:innen mit rheumatoider Arthritis (RA) im Alter ab 50 Jahren mit mindestens einem weiteren kardiovaskulären Risikofaktor zu einem erhöhten Auftreten bösartiger Erkrankungen bei dem JAKi Tofacitinib im Vergleich zu Tumornekrosefaktorinhibitoren kommt. Dieses Ergebnis wurde in anderen Studien seither jedoch nicht bestätigt. In einer Auswertung des deutschen RABBIT-Registers wurde nun ein insgesamt leicht erhöhtes Krebsrisiko bei jemals mit JAKi behandelten gegenüber jemals mit biologischen (b) krankheitsmodifizierenden Antirheumatika (DMARDs) behandelten RA-Patient:innen beobachtet. Während oder nach 2285 JAKi- und 4259 bDMARD-Behandlungsepisoden traten 88 bzw. 135 bösartige Erkrankungen auf, pro 1000 Patient:innenjahre waren das 11,6 (95 %-Konfidenzintervall (KI): 9,3–14,3) Ereignisse bei JAKis und 8,9 (95%-KI: 7,4–10,5) Ereignisse bei bDMARDs. Das adjustierte Hazard Ratio betrug 1,40 (95%-KI: 1,09–1,80) und war damit jener aus der ORAL Surveillance-Studie vergleichbar. Besonders von der beobachteten Risikoerhöhung betroffen waren Patient:innen ab 60 Jahren, mit einer hohen Krankheitsaktivität oder ≥ 3 früheren Behandlungen mit konventionellen synthetischen DMARDs. Weitere überdurchschnittlich betroffene Gruppen waren Raucher:innen, Männer sowie Patient:innen mit über 10 Jahren RA-Krankheitsdauer. Behandelnde sollten mit Risikopatient:innen sorgfältig gemeinsam abwägen, ob die beobachtete Risikoerhöhung die potenziellen Risiken des Absetzens oder des Vorenthaltens einer hochwirksamen Therapie mit einem JAKi überwiegt – denn auch eine unzureichende Krankheitskontrolle führt zu einem erhöhten Krebsrisiko. Die Ergebnisse aus RABBIT sollten Ärzt:innen im Zweifel nicht davon abhalten, Patient:innen, die eine JAKi-Therapie benötigen, mit dieser zu behandeln. Ein Ausweg könnte vielmehr sein, bei JAKi-Therapie von Risikopatient:innen auf eine engmaschige Krebsvorsorge zu achten.
- 20 October 2025
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 85 (1) , 65-69
Open AccessNeue Erkenntnisse aus dem RABBIT-Register zum Krebsrisiko von Patient:innen mit rheumatoider Arthritis bei Therapie mit Januskinaseinhibitoren
Zusammenfassung: Januskinaseinhibitoren (JAKis) sind sehr wirksame Medikamente zur Behandlung entzündlich rheumatischer Erkrankungen. In der randomisierten Studie ORAL Surveillance wurde gezeigt, dass es bei Patient:innen mit rheumatoider Arthritis (RA) im Alter ab 50 Jahren mit mindestens einem weiteren kardiovaskulären Risikofaktor zu einem erhöhten Auftreten bösartiger Erkrankungen bei dem JAKi Tofacitinib im Vergleich zu Tumornekrosefaktorinhibitoren kommt. Dieses Ergebnis wurde in anderen Studien seither jedoch nicht bestätigt. In einer Auswertung des deutschen RABBIT-Registers wurde nun ein insgesamt leicht erhöhtes Krebsrisiko bei jemals mit JAKi behandelten gegenüber jemals mit biologischen (b) krankheitsmodifizierenden Antirheumatika (DMARDs) behandelten RA-Patient:innen beobachtet. Während oder nach 2285 JAKi- und 4259 bDMARD-Behandlungsepisoden traten 88 bzw. 135 bösartige Erkrankungen auf, pro 1000 Patient:innenjahre waren das 11,6 (95 %-Konfidenzintervall (KI): 9,3–14,3) Ereignisse bei JAKis und 8,9 (95%-KI: 7,4–10,5) Ereignisse bei bDMARDs. Das adjustierte Hazard Ratio betrug 1,40 (95%-KI: 1,09–1,80) und war damit jener aus der ORAL Surveillance-Studie vergleichbar. Besonders von der beobachteten Risikoerhöhung betroffen waren Patient:innen ab 60 Jahren, mit einer hohen Krankheitsaktivität oder ≥ 3 früheren Behandlungen mit konventionellen synthetischen DMARDs. Weitere überdurchschnittlich betroffene Gruppen waren Raucher:innen, Männer sowie Patient:innen mit über 10 Jahren RA-Krankheitsdauer. Behandelnde sollten mit Risikopatient:innen sorgfältig gemeinsam abwägen, ob die beobachtete Risikoerhöhung die potenziellen Risiken des Absetzens oder des Vorenthaltens einer hochwirksamen Therapie mit einem JAKi überwiegt – denn auch eine unzureichende Krankheitskontrolle führt zu einem erhöhten Krebsrisiko. Die Ergebnisse aus RABBIT sollten Ärzt:innen im Zweifel nicht davon abhalten, Patient:innen, die eine JAKi-Therapie benötigen, mit dieser zu behandeln. Ein Ausweg könnte vielmehr sein, bei JAKi-Therapie von Risikopatient:innen auf eine engmaschige Krebsvorsorge zu achten.
- Top Cited PapersOpen Access
- 25 June 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (11) , 1779-1790
Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register
- 25 June 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (11) , 1779-1790
Top Cited PapersOpen AccessComparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register
- Open Access
- 30 May 2024
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (11) , 1584-1595
Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry
Objectives To investigate the frequency and factors associated with disease flare following vaccination against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMDs). Methods Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine physician-reported registry were used. Factors associated with flare in patients with I-RMDs were investigated using multivariable logistic regression adjusted for demographic and clinical factors. Results The study included 7336 patients with I-RMD, with 272 of 7336 (3.7%) experiencing flares and 121 of 7336 (1.6%) experiencing flares requiring starting a new medication or increasing the dosage of an existing medication. Factors independently associated with increased odds of flare were: female sex (OR=1.40, 95% CI=1.05 to 1.87), active disease at the time of vaccination (low disease activity (LDA), OR=1.45, 95% CI=1.08 to 1.94; moderate/high disease activity (M/HDA), OR=1.37, 95% CI=0.97 to 1.95; vs remission), and cessation/reduction of antirheumatic medication before or after vaccination (OR=4.76, 95% CI=3.44 to 6.58); factors associated with decreased odds of flare were: higher age (OR=0.90, 95% CI=0.83 to 0.98), non-Pfizer/AstraZeneca/Moderna vaccines (OR=0.10, 95% CI=0.01 to 0.74; vs Pfizer), and exposure to methotrexate (OR=0.57, 95% CI=0.37 to 0.90), tumour necrosis factor inhibitors (OR=0.55, 95% CI=0.36 to 0.85) or rituximab (OR=0.27, 95% CI=0.11 to 0.66), versus no antirheumatic treatment. In a multivariable model using new medication or dosage increase due to flare as the dependent variable, only the following independent associations were observed: active disease (LDA, OR=1.47, 95% CI=0.94 to 2.29; M/HDA, OR=3.08, 95% CI=1.91 to 4.97; vs remission), cessation/reduction of antirheumatic medication before or after vaccination (OR=2.24, 95% CI=1.33 to 3.78), and exposure to methotrexate (OR=0.48, 95% CI=0.26 to 0.89) or rituximab (OR=0.10, 95% CI=0.01 to 0.77), versus no antirheumatic treatment. Conclusion I-RMD flares following SARS-CoV-2 vaccination were uncommon. Factors associated with flares were identified, namely higher disease activity and cessation/reduction of antirheumatic medications before or after vaccination.
- 30 May 2024
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (11) , 1584-1595
Open AccessFactors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry
Objectives To investigate the frequency and factors associated with disease flare following vaccination against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMDs). Methods Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine physician-reported registry were used. Factors associated with flare in patients with I-RMDs were investigated using multivariable logistic regression adjusted for demographic and clinical factors. Results The study included 7336 patients with I-RMD, with 272 of 7336 (3.7%) experiencing flares and 121 of 7336 (1.6%) experiencing flares requiring starting a new medication or increasing the dosage of an existing medication. Factors independently associated with increased odds of flare were: female sex (OR=1.40, 95% CI=1.05 to 1.87), active disease at the time of vaccination (low disease activity (LDA), OR=1.45, 95% CI=1.08 to 1.94; moderate/high disease activity (M/HDA), OR=1.37, 95% CI=0.97 to 1.95; vs remission), and cessation/reduction of antirheumatic medication before or after vaccination (OR=4.76, 95% CI=3.44 to 6.58); factors associated with decreased odds of flare were: higher age (OR=0.90, 95% CI=0.83 to 0.98), non-Pfizer/AstraZeneca/Moderna vaccines (OR=0.10, 95% CI=0.01 to 0.74; vs Pfizer), and exposure to methotrexate (OR=0.57, 95% CI=0.37 to 0.90), tumour necrosis factor inhibitors (OR=0.55, 95% CI=0.36 to 0.85) or rituximab (OR=0.27, 95% CI=0.11 to 0.66), versus no antirheumatic treatment. In a multivariable model using new medication or dosage increase due to flare as the dependent variable, only the following independent associations were observed: active disease (LDA, OR=1.47, 95% CI=0.94 to 2.29; M/HDA, OR=3.08, 95% CI=1.91 to 4.97; vs remission), cessation/reduction of antirheumatic medication before or after vaccination (OR=2.24, 95% CI=1.33 to 3.78), and exposure to methotrexate (OR=0.48, 95% CI=0.26 to 0.89) or rituximab (OR=0.10, 95% CI=0.01 to 0.77), versus no antirheumatic treatment. Conclusion I-RMD flares following SARS-CoV-2 vaccination were uncommon. Factors associated with flares were identified, namely higher disease activity and cessation/reduction of antirheumatic medications before or after vaccination.
- Open Access
Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register
Objectives To investigate the impact of disease activity and treatment with disease-modifying antirheumatic drugs (DMARDs) on all-cause mortality in patients with rheumatoid arthritis and prevalent interstitial lung disease (RA-ILD). Methods Patients with RA-ILD were selected from the biologics register Rheumatoid Arthritis: Observation of Biologic Therapy (RABBIT). Using time-varying Cox regression, the association between clinical measures and mortality was investigated. The impact of DMARDs was analysed by (1) Cox regression considering cumulative exposure (ie, treatment months divided by total months) and (2) time-varying Cox regression as main approach (treatment exposures at monthly level). Results Out of 15 566 participants, 381 were identified as RA-ILD cases with 1258 person-years of observation and 2.6 years median length of follow-up. Ninety-seven patients (25.5%) died and 34 (35.1%) of these were not receiving DMARD therapy at the time of death. Higher inflammatory biomarkers but not swollen and tender joint count were significantly associated with mortality. Compared with tumour necrosis factor inhibitors (TNFi), non-TNFi biologic DMARDs (bDMARDs) exhibited adjusted HRs (aHRs) for mortality below 1, lacking statistical significance. This finding was stable in various sensitivity analyses. Joint aHR for non-TNFi biologics and JAKi versus TNFi was 0.56 (95% CI 0.33 to 0.97). Receiving no DMARD treatment was associated with a twofold higher mortality risk compared with receiving any DMARD treatment, aHR 2.03 (95% CI 1.23 to 3.35). Conclusions Inflammatory biomarkers and absence of DMARD treatment were associated with increased risk of mortality in patients with RA-ILD. Non-TNFi bDMARDs may confer enhanced therapeutic benefits in patients with RA-ILD.
Open AccessImpact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register
Objectives To investigate the impact of disease activity and treatment with disease-modifying antirheumatic drugs (DMARDs) on all-cause mortality in patients with rheumatoid arthritis and prevalent interstitial lung disease (RA-ILD). Methods Patients with RA-ILD were selected from the biologics register Rheumatoid Arthritis: Observation of Biologic Therapy (RABBIT). Using time-varying Cox regression, the association between clinical measures and mortality was investigated. The impact of DMARDs was analysed by (1) Cox regression considering cumulative exposure (ie, treatment months divided by total months) and (2) time-varying Cox regression as main approach (treatment exposures at monthly level). Results Out of 15 566 participants, 381 were identified as RA-ILD cases with 1258 person-years of observation and 2.6 years median length of follow-up. Ninety-seven patients (25.5%) died and 34 (35.1%) of these were not receiving DMARD therapy at the time of death. Higher inflammatory biomarkers but not swollen and tender joint count were significantly associated with mortality. Compared with tumour necrosis factor inhibitors (TNFi), non-TNFi biologic DMARDs (bDMARDs) exhibited adjusted HRs (aHRs) for mortality below 1, lacking statistical significance. This finding was stable in various sensitivity analyses. Joint aHR for non-TNFi biologics and JAKi versus TNFi was 0.56 (95% CI 0.33 to 0.97). Receiving no DMARD treatment was associated with a twofold higher mortality risk compared with receiving any DMARD treatment, aHR 2.03 (95% CI 1.23 to 3.35). Conclusions Inflammatory biomarkers and absence of DMARD treatment were associated with increased risk of mortality in patients with RA-ILD. Non-TNFi bDMARDs may confer enhanced therapeutic benefits in patients with RA-ILD.
- 7 November 2023
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (2) , 274-287
Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry
Objective: Approximately one third of individuals worldwide have not received a COVID‐19 vaccine. Although studies have investigated risk factors linked to severe COVID‐19 among unvaccinated people with rheumatic diseases (RDs), we know less about whether these factors changed as the pandemic progressed. We aimed to identify risk factors associated with severe COVID‐19 in unvaccinated individuals in different pandemic epochs corresponding to major variants of concern.Methods: Patients with RDs and COVID‐19 were entered into the COVID‐19 Global Rheumatology Alliance Registry between March 2020 and June 2022. An ordinal logistic regression model (not hospitalized, hospitalized, and death) was used with date of COVID‐19 diagnosis, age, sex, race and/or ethnicity, comorbidities, RD activity, medications, and the human development index (HDI) as covariates. The main analysis included all unvaccinated patients across COVID‐19 pandemic epochs; subanalyses stratified patients according to RD types.Results: Among 19,256 unvaccinated people with RDs and COVID‐19, those who were older, male, had more comorbidities, used glucocorticoids, had higher disease activity, or lived in lower HDI regions had worse outcomes across epochs. For those with rheumatoid arthritis, sulfasalazine and B‐cell–depleting therapy were associated with worse outcomes, and tumor necrosis factor inhibitors were associated with improved outcomes. In those with connective tissue disease or vasculitis, B‐cell–depleting therapy was associated with worse outcomes.Conclusion: Risk factors for severe COVID‐19 outcomes were similar throughout pandemic epochs in unvaccinated people with RDs. Ongoing efforts, including vaccination, are needed to reduce COVID‐19 severity in this population, particularly in those with medical and social vulnerabilities identified in this study.
- 7 November 2023
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (2) , 274-287
Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry
Objective: Approximately one third of individuals worldwide have not received a COVID‐19 vaccine. Although studies have investigated risk factors linked to severe COVID‐19 among unvaccinated people with rheumatic diseases (RDs), we know less about whether these factors changed as the pandemic progressed. We aimed to identify risk factors associated with severe COVID‐19 in unvaccinated individuals in different pandemic epochs corresponding to major variants of concern.Methods: Patients with RDs and COVID‐19 were entered into the COVID‐19 Global Rheumatology Alliance Registry between March 2020 and June 2022. An ordinal logistic regression model (not hospitalized, hospitalized, and death) was used with date of COVID‐19 diagnosis, age, sex, race and/or ethnicity, comorbidities, RD activity, medications, and the human development index (HDI) as covariates. The main analysis included all unvaccinated patients across COVID‐19 pandemic epochs; subanalyses stratified patients according to RD types.Results: Among 19,256 unvaccinated people with RDs and COVID‐19, those who were older, male, had more comorbidities, used glucocorticoids, had higher disease activity, or lived in lower HDI regions had worse outcomes across epochs. For those with rheumatoid arthritis, sulfasalazine and B‐cell–depleting therapy were associated with worse outcomes, and tumor necrosis factor inhibitors were associated with improved outcomes. In those with connective tissue disease or vasculitis, B‐cell–depleting therapy was associated with worse outcomes.Conclusion: Risk factors for severe COVID‐19 outcomes were similar throughout pandemic epochs in unvaccinated people with RDs. Ongoing efforts, including vaccination, are needed to reduce COVID‐19 severity in this population, particularly in those with medical and social vulnerabilities identified in this study.
- Top Cited PapersOpen Access
Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
Objective To estimate the effects of Janus kinase inhibitors (JAKi), tumour necrosis factor inhibitors (TNFi), other biologic(b) or conventional synthetic(cs) disease-modifying antirheumatic drugs (DMARDs) on the risk of major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA). Methods Cohort study analysing episodes of DMARD-treatment initiated between January 2017 and April 2022 in the biologics register Rheumatoid Arthritis: Observation of Biologic Therapy. Incidence rates (IRs) per 100 patient-years with 95% CIs were calculated for overall patients and those with cardiovascular risk (age ≥50 years and ≥1 cardiovascular risk factor). MACE risk was estimated as HRs by inverse probability of treatment weight-adjusted Andersen-Gill models. Results A total of 154 MACE occurred among 14 203 treatment episodes (21 218 patient-years). IRs were 0.68 (0.47; 0.95), 0.62 (0.45; 0.83), 0.76 (0.53; 1.06) and 0.95 (0.68; 1.29) for JAKi, TNFi, bDMARDs and csDMARDs, respectively. IRs were higher in cardiovascular risk patients. Adjusted HRs (95% CI) comparing JAKi, bDMARDs and csDMARDs with TNFi were 0.89 (0.52 to 1.52), 0.76 (0.45; to1.27) and 1.36 (0.85 to 2.19) in overall, and 0.74 (0.41 to 1.31), 0.75 (0.45 to 1.27) and 1.21 (0.74 to 1.98) in cardiovascular risk patients. HRs were not increased in patients ≥65 years, with cardiovascular history or smokers, and also not when using csDMARD as reference instead of TNFi. IRs for baricitinib, tofacitinib and upadacitinib were 0.49 (0.25 to 0.85), 0.98 (0.58 to 1.55) and 0.53 (0.15 to 1.36), respectively. Conclusion In this German observational cohort study, MACE did not occur more frequently with JAKi compared with other DMARDs. However, individual JAKis showed different unadjusted IRs.
Top Cited PapersOpen AccessRisk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
Objective To estimate the effects of Janus kinase inhibitors (JAKi), tumour necrosis factor inhibitors (TNFi), other biologic(b) or conventional synthetic(cs) disease-modifying antirheumatic drugs (DMARDs) on the risk of major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA). Methods Cohort study analysing episodes of DMARD-treatment initiated between January 2017 and April 2022 in the biologics register Rheumatoid Arthritis: Observation of Biologic Therapy. Incidence rates (IRs) per 100 patient-years with 95% CIs were calculated for overall patients and those with cardiovascular risk (age ≥50 years and ≥1 cardiovascular risk factor). MACE risk was estimated as HRs by inverse probability of treatment weight-adjusted Andersen-Gill models. Results A total of 154 MACE occurred among 14 203 treatment episodes (21 218 patient-years). IRs were 0.68 (0.47; 0.95), 0.62 (0.45; 0.83), 0.76 (0.53; 1.06) and 0.95 (0.68; 1.29) for JAKi, TNFi, bDMARDs and csDMARDs, respectively. IRs were higher in cardiovascular risk patients. Adjusted HRs (95% CI) comparing JAKi, bDMARDs and csDMARDs with TNFi were 0.89 (0.52 to 1.52), 0.76 (0.45; to1.27) and 1.36 (0.85 to 2.19) in overall, and 0.74 (0.41 to 1.31), 0.75 (0.45 to 1.27) and 1.21 (0.74 to 1.98) in cardiovascular risk patients. HRs were not increased in patients ≥65 years, with cardiovascular history or smokers, and also not when using csDMARD as reference instead of TNFi. IRs for baricitinib, tofacitinib and upadacitinib were 0.49 (0.25 to 0.85), 0.98 (0.58 to 1.55) and 0.53 (0.15 to 1.36), respectively. Conclusion In this German observational cohort study, MACE did not occur more frequently with JAKi compared with other DMARDs. However, individual JAKis showed different unadjusted IRs.
- 20 March 2023
- Published by Springer Nature in InFo Neurologie + Psychiatrie
- Vol. 25 (3) , 40-49
Moderne Therapie bipolarer Störungen
- 20 March 2023
- Published by Springer Nature in InFo Neurologie + Psychiatrie
- Vol. 25 (3) , 40-49
Moderne Therapie bipolarer Störungen
- Open Access
- 14 February 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (5) , 698-709
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Objectives To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression. Results Of 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25–2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39–2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42–0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19. Conclusion Older age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics.
- 14 February 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (5) , 698-709
Open AccessCharacteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Objectives To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression. Results Of 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25–2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39–2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42–0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19. Conclusion Older age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics.